---
figid: PMC3228010__onc0071006090001
figtitle: Signaling pathways of sunitinib and sorafenib cardiotoxicity
organisms:
- Homo sapiens
pmcid: PMC3228010
filename: onc0071006090001.jpg
figlink: /pmc/articles/PMC3228010/figure/F1/
number: F1
caption: Signaling pathways of sunitinib and sorafenib cardiotoxicity. Sunitinib,
  by inhibiting the ribosomal S6 kinase (RSK), allows the release of the proapoptotic
  factor BCL2-associated death promoter (BAD) from RSK inactivation; BAD interacts
  with BCL2 associated X protein (BAX), which, in turn, causes the release of cytochrome
  c (Cyt C), leading to caspase activation and cell death. Moreover, sunitinib, counteracting
  adenosine monophosphate activated protein kinase (AMPK), fosters protein translation
  and lipid biosynthesis through eukaryotic elongation factor 2 (EEF2), mammalian
  target of rapamycin (mTOR), and acetyl coenzyme A carboxylase (ACC). Sorafenib,
  preventing v-raf-1 murine leukemia viral oncogene homolog 1 (RAF1)/extracellular
  signal regulated kinase (ERK) formation, disrupts the ERK-mediated prosurvival pathway;
  furthermore, sorafenib, inhibiting the proapoptotic kinases apoptosis signal-regulating
  kinase 1 (ASK1) and mammalian sterile 20 kinase 2 (MST2), through RAF1, triggers
  cell death.
papertitle: 'Cardiovascular Safety of VEGF-Targeting Therapies: Current Evidence and
  Handling Strategies.'
reftext: Fabio Girardi, et al. Oncologist. 2010 Jul;15(7):683-694.
year: '2010'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9622288
figid_alias: PMC3228010__F1
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC3228010__F1
ndex: a95e2416-ded9-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3228010__onc0071006090001.html
  '@type': Dataset
  description: Signaling pathways of sunitinib and sorafenib cardiotoxicity. Sunitinib,
    by inhibiting the ribosomal S6 kinase (RSK), allows the release of the proapoptotic
    factor BCL2-associated death promoter (BAD) from RSK inactivation; BAD interacts
    with BCL2 associated X protein (BAX), which, in turn, causes the release of cytochrome
    c (Cyt C), leading to caspase activation and cell death. Moreover, sunitinib,
    counteracting adenosine monophosphate activated protein kinase (AMPK), fosters
    protein translation and lipid biosynthesis through eukaryotic elongation factor
    2 (EEF2), mammalian target of rapamycin (mTOR), and acetyl coenzyme A carboxylase
    (ACC). Sorafenib, preventing v-raf-1 murine leukemia viral oncogene homolog 1
    (RAF1)/extracellular signal regulated kinase (ERK) formation, disrupts the ERK-mediated
    prosurvival pathway; furthermore, sorafenib, inhibiting the proapoptotic kinases
    apoptosis signal-regulating kinase 1 (ASK1) and mammalian sterile 20 kinase 2
    (MST2), through RAF1, triggers cell death.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - RPS6KA1
  - RPS6KA2
  - RPS6KA3
  - RPS6KA4
  - RPS6KA5
  - RPS6KA6
  - RPS6KB1
  - RPS6KB2
  - RAF1
  - RNASE3
  - STK3
  - PRKAA1
  - PRKAA2
  - PRKAB1
  - PRKAB2
  - PRKAG1
  - PRKAG2
  - PRKAG3
  - BAD
  - MTOR
  - MAP3K5
  - ACACA
  - BMS1
  - ACACB
  - EEF2
  - BAX
  - EPHB2
  - MAPK1
  - MAPK3
  - CASP1
  - CASP2
  - CASP4
  - CASP5
  - CASP6
  - CASP8
  - CASP9
  - CASP10
  - CASP12
  - CASP14
  - CASP3
  - CASP7
---
